Cardiovascular adverse effects during itraconazole therapy

Sl, Fung; Ch, Chau; Ww, Yew

doi:10.1183/09031936.00021208

Cited by 29 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…89 On the basis of these data, the FDA recommends avoiding itraconazole in patients with ventricular dysfunction or a history of HF for onychomycosis and only to consider itraconazole in case of life-threatening fungal infections. [85][86][87][88][89][90] Other Antifungal Medications Several cases of new-onset dilated cardiomyopathy with subsequent HF with amphotericin B and its liposomal e45 formulation have been reported. [91][92][93] In each case, HF symptoms and echocardiographic findings normalized on discontinuation of therapy, which occurred within 10 days to 6 months of drug discontinuation.…”

Section: Anti-infective Medicationsmentioning

confidence: 99%

“…[85][86][87][88][89][90] Using the FDA Adverse Event Reporting System from 1992 to 2001, Ahmad et al 89 found 58 cases of HF in patients administered itraconazole. Because of potential confounders such as hypertension, valvular heart disease, and history of HF, causality was not determined; however, of the 58 patients, there were 28 admissions to the hospital and 13 deaths.…”

Section: Anti-infective Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Drugs That May Cause or Exacerbate Heart Failure

Page¹,

O’Bryant²,

Cheng³

et al. 2016

Circulation

348

185

View full text Add to dashboard Cite

Heart failure is a common, costly, and debilitating syndrome that is associated with a highly complex drug regimen, a large number of comorbidities, and a large and often disparate number of healthcare providers. All of these factors conspire to increase the risk of heart failure exacerbation by direct myocardial toxicity, drug-drug interactions, or both. This scientific statement is designed to serve as a comprehensive and accessible source of drugs that may cause or exacerbate heart failure to assist healthcare providers in improving the quality of care for these patients.

show abstract

Section: Anti-infective Medicationsmentioning

confidence: 99%

Section: Anti-infective Medicationsmentioning

confidence: 99%

Drugs That May Cause or Exacerbate Heart Failure

Page¹,

O’Bryant²,

Cheng³

et al. 2016

Circulation

348

185

View full text Add to dashboard Cite

show abstract

“…5 It has been noted in the literature that patients with underlying chronic disease are at increased risk for developing CHF symptoms when taking itraconazole. 10 Although we feel strongly that itraconazole was the etiology for our patient's CHF exacerbations, we cannot discount the fact that our patient had underlying issues that could have lent support to the adverse events. For example, our patient's RA therapy had, for some time, included infliximab, which has been associated with drug-induced CHF; however, the drug was discontinued in June 2008 before the initial CHF event.…”

Section: Discussionmentioning

confidence: 87%

Congestive Heart Failure Exacerbation Secondary to Itraconazole Therapy

Liedtke¹,

Vandaveer²,

Greenfield³

et al. 2011

Infectious Diseases in Clinical Practice

View full text Add to dashboard Cite

Itraconazole is a commonly prescribed antifungal agent that has been associated with the occurrence of congestive heart failure (CHF) symptoms. There is currently a black box warning related to itraconazole stating that its use is contraindicated for the treatment of onychomycosis in patients with left ventricular dysfunction or a history of CHF. We report a case of a man presenting with 3 exacerbations of CHF secondary to itraconazole therapy for disseminated histoplasmosis. He was successfully treated with posaconazole with no recurrence of symptoms.

show abstract

“…A number of longer-term toxicities may manifest over time especially with triazoles, including cardiovascular dysfunction (especially itraconazole) (Fung et al 2008), phototoxic reactions, increased risk of squamous cell carcinoma (voriconazole) (Clancy and Nguyen 2011), fluoride excess, periostitis with voriconazole (Wermers et al 2011), and peripheral neuropathies (Baxter et al 2011). Therefore, proactive screening for these long-term toxicities and continuous reassessment of the risk versus benefit of continuing therapy is essential among patients who remain on antifungal therapy for prolonged periods.…”

Section: Principle 3: It Is Important For the Clinician To Know The Pmentioning

confidence: 99%

Treatment Principles for the Management of Mold Infections

Kontoyiannis

Lewis

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Survival rates among immunocompromised patients with invasive mold infections have markedly improved over the last decade with earlier diagnosis and new antifungal treatment options. Yet, increasing antifungal resistance, breakthrough infections with intrinsically resistant fungi, and potentially life-threatening adverse effects and drug interactions are becoming more problematic, especially with prolonged therapy. Evidence-based recommendations for treating invasive aspergillosis and mucormycosis provide excellent guidance on the initial workup and treatment of these molds, but they cannot address all of the key management issues. Herein, we discuss 10 general treatment principles in the management of invasive mold disease in immunocompromised patients and discuss how these principles can be integrated to develop an effective, individualized treatment plan.

show abstract

Cardiovascular adverse effects during itraconazole therapy

Cited by 29 publications

References 6 publications

Drugs That May Cause or Exacerbate Heart Failure

Drugs That May Cause or Exacerbate Heart Failure

Congestive Heart Failure Exacerbation Secondary to Itraconazole Therapy

Treatment Principles for the Management of Mold Infections

Contact Info

Product

Resources

About